Seppic’s Sepivac SWETM vaccine adjuvant for human use can contribute to the development of vaccine solutions to fight seasonal and pandemic influenza, as well as COVID-19.
Together with various international partners, Seppic is participating in the global research effort to develop a vaccine solution against COVID-19. These programs are in the pre-clinical phase and some of them should move to the clinical study stage by the end of this year.
Seppic’s open-access solution is designed for academics, biotech companies and pharmaceutical manufacturers to accelerate the development of innovative vaccines.
Sepivac SWETM is the result of several years of co-development with the Vaccine Formulation Institute (VFI), a non-profit organisation that aims to make the safest and most effective adjuvant technologies available to all vaccine developers. This ready-to-use adjuvant is based on a technology recognized for its efficacy and good safety profile in seasonal and pandemic influenza vaccines.
Jean-Baptiste Dellon, CEO of Seppic, states: “Seppic has been a player for more than 40 years in the field of vaccine adjuvants. Today, Seppic contributes to accelerate the research of innovative vaccines by proposing an adjuvant used in the composition of vaccines against COVID-19. Making this adjuvant available to the entire community of vaccine developers, at an industrial scale, is a major step to help advance vaccine research.”
Image credit: Kristina Wook
